Document Detail


Effect of combined treatment with alpha-Lipoic acid and acetyl-L-carnitine on vascular function and blood pressure in patients with coronary artery disease.
MedLine Citation:
PMID:  17396066     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Mitochondria produce reactive oxygen species that may contribute to vascular dysfunction. alpha-Lipoic acid and acetyl-L-carnitine reduce oxidative stress and improve mitochondrial function. In a double-blind crossover study, the authors examined the effects of combined alpha-lipoic acid/acetyl-L-carnitine treatment and placebo (8 weeks per treatment) on vasodilator function and blood pressure in 36 subjects with coronary artery disease. Active treatment increased brachial artery diameter by 2.3% (P=.008), consistent with reduced arterial tone. Active treatment tended to decrease systolic blood pressure for the whole group (P=.07) and had a significant effect in the subgroup with blood pressure above the median (151+/-20 to 142+/-18 mm Hg; P=.03) and in the subgroup with the metabolic syndrome (139+/-21 to 130+/-18 mm Hg; P=.03). Thus, mitochondrial dysfunction may contribute to the regulation of blood pressure and vascular tone. Further studies are needed to confirm these findings and determine the clinical utility of alpha-lipoic acid/acetyl-L-carnitine as antihypertensive therapy.
Authors:
Craig J McMackin; Michael E Widlansky; Naomi M Hamburg; Alex L Huang; Susan Weller; Monika Holbrook; Noyan Gokce; Tory M Hagen; John F Keaney; Joseph A Vita
Related Documents :
16407686 - Attempted forced titration of blood pressure to <130/85 mm hg in type 2 diabetic hypert...
2904756 - The addition of doxazosin to the treatment regimen of hypertensive patients not respons...
1285936 - Comparative effects of nitrendipine and hydrochlorothiazide on calciotropic hormones an...
20535716 - Short-term antihypertensive efficacy of perindopril according to clinical profile of 3,...
9442476 - Aortic peak flow velocity as an index of myocardial contractility in the conscious rat.
9406146 - An overview of the influence of ace inhibitors on fetal-placental circulation and perin...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural    
Journal Detail:
Title:  Journal of clinical hypertension (Greenwich, Conn.)     Volume:  9     ISSN:  1524-6175     ISO Abbreviation:  J Clin Hypertens (Greenwich)     Publication Date:  2007 Apr 
Date Detail:
Created Date:  2007-03-30     Completed Date:  2007-08-10     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  100888554     Medline TA:  J Clin Hypertens (Greenwich)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  249-55     Citation Subset:  IM    
Affiliation:
Evans Department of Medicine and Whitaker Cardovascular Institute, Boston University School of Medicine, Boston, MA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acetylcarnitine / metabolism,  therapeutic use*
Aged
Analysis of Variance
Biological Markers / blood,  urine
Blood Flow Velocity / drug effects
Blood Pressure / drug effects*
Boston
Brachial Artery / drug effects,  physiopathology
Coronary Artery Disease / drug therapy*,  metabolism,  physiopathology*
Cross-Over Studies
Double-Blind Method
Drug Therapy, Combination
Endothelium, Vascular / drug effects*,  metabolism,  physiopathology*
Female
Humans
Male
Middle Aged
Research Design
Thioctic Acid / therapeutic use*
Treatment Outcome
Vasodilation / drug effects
Vitamin B Complex / therapeutic use*
Grant Support
ID/Acronym/Agency:
HL060886/HL/NHLBI NIH HHS; K12 HL083781-01/HL/NHLBI NIH HHS; K12 HL083781-02/HL/NHLBI NIH HHS; P01 HL060886-01A1/HL/NHLBI NIH HHS; P01 HL060886-01A10004/HL/NHLBI NIH HHS; P01 HL060886-02/HL/NHLBI NIH HHS; P01 HL060886-020004/HL/NHLBI NIH HHS; P01 HL060886-03/HL/NHLBI NIH HHS; P01 HL060886-030004/HL/NHLBI NIH HHS; P01 HL060886-04/HL/NHLBI NIH HHS; P01 HL060886-040004/HL/NHLBI NIH HHS; P01 HL060886-05/HL/NHLBI NIH HHS; P01 HL060886-050004/HL/NHLBI NIH HHS; P01 HL081587-010005/HL/NHLBI NIH HHS; P50 HL083801-01/HL/NHLBI NIH HHS; P50 HL083801-010001/HL/NHLBI NIH HHS; P50 HL083801-017464/HL/NHLBI NIH HHS; R01 HL075795-01/HL/NHLBI NIH HHS; R01 HL083269-01A1/HL/NHLBI NIH HHS; T32 HL 07224/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Biological Markers; 12001-76-2/Vitamin B Complex; 14992-62-2/Acetylcarnitine; 62-46-4/Thioctic Acid
Comments/Corrections
Comment In:
J Clin Hypertens (Greenwich). 2007 Apr;9(4):285-6   [PMID:  17396072 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Maximizing smoking cessation in clinical practice: pharmacologic and behavioral interventions.
Next Document:  Effects of warfarin on blood pressure in men with diabetes and hypertension--a longitudinal study.